Launch Excellence Transforming Post-HCT Care for Blood Cancer Patients - Insights from Oncologists Introduction: Omisirge, the revolutionary stem cell therapy developed by Gamida Cell, has recently received FDA approval and is poised to revolutionize the post-HCT (hematopoietic stem cell transplantation) journey for patients with blood cancers.
